Filter Results
Clinical Studies
Results filtered:Study status:
Contact Us for the Latest Status
Contact Us for the Latest Status
-
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of BMS-986393 in Novel Combinations in Participants with Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component
Rochester, Minn.,
Jacksonville, Fla.,
Scottsdale/Phoenix, Ariz.
The purpose of this study is to determine the safety and tolerability of BMS-986393 in combination with alnuctamab, mezigdomide, or iberdomide in participants with relapsed or refractory multiple myeloma (RRMM), and to define the RP2D of alnuctamab, mezigdomide, or iberdomide in combination with BMS-986393 in participants with (RRMM).
.